Mark J. Ratain to Feasibility Studies
This is a "connection" page, showing publications Mark J. Ratain has written about Feasibility Studies.
Connection Strength
0.090
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
Score: 0.041
-
Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol. 1991 May; 9(5):871-6.
Score: 0.020
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.012
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.008
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.008